Preparation and Evaluation of Rifampicin and Co-trimoxazole-loaded Nanocarrier Against Brucella Melitensis Infection

Overview

Journal Iran Biomed J

Specialties Biology
General Medicine

Date 2017 Oct 17

PMID 29031243

Citations 6

Authors

Narges Bodaghabadi

Samira Hajigholami

Ziba Vaise Malekshahi

Maliheh Entezari

Farhood Najafi

Hadi Shirzad

Majid Sadeghizadeh

Affiliations

Soon will be listed here.

Abstract

Background: Brucellosis or Malta fever is a contagious infection common between human and domestic animals. Many antibiotics are used for brucellosis treatment, but they are not efficient and put heavy burden on society. Co-trimoxazole and rifampicin are two candidates for brucellosis treatment. In this study, we aimed to enhance the efficacy of these antibiotics using designed nanoparticles.

Methods: Different concentrations of co-trimoxazole and rifampicin were used for loading onto a nanostructure of synthesized monomethoxy poly(ethylene glycol)-oleate (mPEG-OA). The solubility, cytotoxicity, and efficacy of these nano-packed antibiotics on Brucella-infected murine phagocytic cells were examined, as compared with free antibiotics. Then the release nanoparticles was increased approximately 3.5 and 1.5fold, respectively, which is considerable in comparison with free insoluble ones.

Results: Despite acceptable loading percentage, the application of co-trimoxazole-loaded nanoparticle on Brucella-infected J774A.1 murine macrophage-like cells did not lead to reduction in the number of bacteria; however, the efficacy of rifampicin on Brucella-infected murine phagocytic cells enhanced.

Conclusion: In the current study, the efficacy of rifampicin on reducing the number of Brucella melitensis increased by the novel synthesized nanostructure. In contrast, since co-trimoxazole efficacy did not enhance by loading onto nanoparticles, the co-trimoxazole inefficiency is most likely not due to its low penetration or insolubility, and probably there are other factors that remain to be clarified in the future investigations.

Citing Articles

Exploring the Therapeutic Potential of Antibiotics in Hyperglycemia-Induced Macrophage Dysfunctions.

Yossapol M, Srinontong P, Aengwanich W, Panil M, Somsup S, Odoi J Antibiotics (Basel). 2025; 14(2).

PMID: 40001441 PMC: 11851781. DOI: 10.3390/antibiotics14020198.

Enhancing Therapeutic Efficacy against Infection in a Murine Model Using Rifampicin-Loaded PLGA Nanoparticles.

Hernandez-Giottonini K, Arellano-Reynoso B, Rodriguez-Cordova R, de la Vega-Olivas J, Diaz-Aparicio E, Lucero-Acuna A ACS Omega. 2024; 8(51):49362-49371.

PMID: 38162745 PMC: 10753543. DOI: 10.1021/acsomega.3c07892.

Combinatorial efficacy of Manuka honey and antibiotics in the control of staphylococci and their small colony variants.

Liang J, Adeleye M, Onyango L Front Cell Infect Microbiol. 2023; 13:1219984.

PMID: 37928190 PMC: 10622673. DOI: 10.3389/fcimb.2023.1219984.

Surveillance of multidrug-resistant tuberculosis in sub-Saharan Africa through wastewater-based epidemiology.

Mtetwa H, Amoah I, Kumari S, Bux F, Reddy P Heliyon. 2023; 9(8):e18302.

PMID: 37576289 PMC: 10412881. DOI: 10.1016/j.heliyon.2023.e18302.

Antibiotic persistence of intracellular Brucella abortus.

Mode S, Ketterer M, Quebatte M, Dehio C PLoS Negl Trop Dis. 2022; 16(7):e0010635.

PMID: 35881641 PMC: 9355222. DOI: 10.1371/journal.pntd.0010635.

References

Kinsara A, Al-Mowallad A, Osoba A . Increasing resistance of Brucellae to co-trimoxazole. Antimicrob Agents Chemother. 1999; 43(6):1531. PMC: 89318. DOI: 10.1128/AAC.43.6.1531. View

Memish Z, Mah M, Al Mahmoud S, Al Shaalan M, Khan M . Brucella bacteraemia: clinical and laboratory observations in 160 patients. J Infect. 2000; 40(1):59-63. DOI: 10.1053/jinf.1999.0586. View

Patel B, Parikh R, Aboti P . Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment. J Drug Deliv. 2013; 2013:370938. PMC: 3759266. DOI: 10.1155/2013/370938. View

Bock N, Sterling T, Hamilton C, Pachucki C, Wang Y, Conwell D . A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment. Am J Respir Crit Care Med. 2002; 165(11):1526-30. DOI: 10.1164/rccm.200201-047OC. View

Philippon A, Kazmierczak A, Nevot P . [Treatment of brucellosis associated with corynebacterium parvum infection in mice with antibiotics (tetracycline, ampicillin, trimethoprim-sulfamethoxazole)]. Ann Inst Pasteur (Paris). 1972; 123(3):349-62. View

Rao B, Murthy K . Preparation and in vitro evaluation of chitosan matrices cross-linked by formaldehyde vapors. Drug Dev Ind Pharm. 2000; 26(10):1085-90. DOI: 10.1081/ddc-100100272. View

Abed N, Couvreur P . Nanocarriers for antibiotics: a promising solution to treat intracellular bacterial infections. Int J Antimicrob Agents. 2014; 43(6):485-96. DOI: 10.1016/j.ijantimicag.2014.02.009. View

Tahmasebi Mirgani M, Isacchi B, Sadeghizadeh M, Marra F, Bilia A, Mowla S . Dendrosomal curcumin nanoformulation downregulates pluripotency genes via miR-145 activation in U87MG glioblastoma cells. Int J Nanomedicine. 2014; 9:403-17. PMC: 3894954. DOI: 10.2147/IJN.S48136. View

Huh A, Kwon Y . "Nanoantibiotics": a new paradigm for treating infectious diseases using nanomaterials in the antibiotics resistant era. J Control Release. 2011; 156(2):128-45. DOI: 10.1016/j.jconrel.2011.07.002. View

10.

Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos E . The new global map of human brucellosis. Lancet Infect Dis. 2006; 6(2):91-9. DOI: 10.1016/S1473-3099(06)70382-6. View

11.

Pal S, Tak Y, Song J . Does the antibacterial activity of silver nanoparticles depend on the shape of the nanoparticle? A study of the Gram-negative bacterium Escherichia coli. Appl Environ Microbiol. 2007; 73(6):1712-20. PMC: 1828795. DOI: 10.1128/AEM.02218-06. View

12.

Hasanjani Roushan M, Mohraz M, Hajiahmadi M, Ramzani A, Valayati A . Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. Clin Infect Dis. 2006; 42(8):1075-80. DOI: 10.1086/501359. View

13.

Walsh C . Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000; 406(6797):775-81. DOI: 10.1038/35021219. View

14.

Gold H, Moellering Jr R . Antimicrobial-drug resistance. N Engl J Med. 1996; 335(19):1445-53. DOI: 10.1056/NEJM199611073351907. View

15.

Erfani-Moghadam V, Nomani A, Zamani M, Yazdani Y, Najafi F, Sadeghizadeh M . A novel diblock of copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells. Int J Nanomedicine. 2014; 9:5541-54. PMC: 4257051. DOI: 10.2147/IJN.S63762. View

16.

Weir E, Lawlor A, Whelan A, Regan F . The use of nanoparticles in anti-microbial materials and their characterization. Analyst. 2008; 133(7):835-45. DOI: 10.1039/b715532h. View

17.

Haque N, Bari M, Hossain M, Muhammad N, Ahmed S, Rahman A . An overview of Brucellosis. Mymensingh Med J. 2011; 20(4):742-7. View

18.

Babaei E, Sadeghizadeh M, Hassan Z, Feizi M, Najafi F, Hashemi S . Dendrosomal curcumin significantly suppresses cancer cell proliferation in vitro and in vivo. Int Immunopharmacol. 2011; 12(1):226-34. DOI: 10.1016/j.intimp.2011.11.015. View

19.

Boucher H, Talbot G, Bradley J, Edwards J, Gilbert D, Rice L . Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2008; 48(1):1-12. DOI: 10.1086/595011. View

20.

Gutierrez Altes A, Diez Enciso M, Pena Garcia P, Campos Bueno A . In vitro activity of N-formimidoyl thienamycin against 98 clinical isolates of Brucella melitensis compared with those of cefoxitin, rifampin, tetracycline, and co-trimoxazole. Antimicrob Agents Chemother. 1982; 21(3):501-3. PMC: 181922. DOI: 10.1128/AAC.21.3.501. View